235 related articles for article (PubMed ID: 25224412)
21. [Role of NK cell receptor-expressing cells in the regulation of GVHD and GVL].
Tanaka J
Rinsho Ketsueki; 2008 Aug; 49(8):598-606. PubMed ID: 18800608
[No Abstract] [Full Text] [Related]
22. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.
Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG
Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207
[TBL] [Abstract][Full Text] [Related]
23. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
24. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
25. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
Yang YG; Qi J; Wang MG; Sykes M
Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
[TBL] [Abstract][Full Text] [Related]
26. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.
Zhao F; Zhang Y; Wang H; Jin M; He S; Shi Y; Guo Y; Zhang Y
Blood; 2011 Feb; 117(5):1723-33. PubMed ID: 21119110
[TBL] [Abstract][Full Text] [Related]
27. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
30. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.
Li N; Matte-Martone C; Zheng H; Cui W; Venkatesan S; Tan HS; McNiff J; Demetris AJ; Roopenian D; Kaech S; Shlomchik WD
Blood; 2011 Nov; 118(22):5965-76. PubMed ID: 21917752
[TBL] [Abstract][Full Text] [Related]
31. Natural regulation of immunity to minor histocompatibility antigens.
Robertson NJ; Chai JG; Millrain M; Scott D; Hashim F; Manktelow E; Lemonnier F; Simpson E; Dyson J
J Immunol; 2007 Mar; 178(6):3558-65. PubMed ID: 17339452
[TBL] [Abstract][Full Text] [Related]
32. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
Sefrioui H; Billiau AD; Waer M
Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.
Marcondes AM; Li X; Tabellini L; Bartenstein M; Kabacka J; Sale GE; Hansen JA; Dinarello CA; Deeg HJ
Blood; 2011 Nov; 118(18):5031-9. PubMed ID: 21900190
[TBL] [Abstract][Full Text] [Related]
36. Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.
Cooper ML; Choi J; Karpova D; Vij K; Ritchey J; Schroeder MA; DiPersio JF
J Immunol; 2017 May; 198(9):3746-3754. PubMed ID: 28330901
[TBL] [Abstract][Full Text] [Related]
37. Graft-versus-leukemia reactions in allogeneic chimeras.
Kolb HJ; Schmid C; Barrett AJ; Schendel DJ
Blood; 2004 Feb; 103(3):767-76. PubMed ID: 12958064
[TBL] [Abstract][Full Text] [Related]
38. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
[TBL] [Abstract][Full Text] [Related]
39. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
[TBL] [Abstract][Full Text] [Related]
40. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Morris ES; MacDonald KP; Hill GR
Blood; 2006 May; 107(9):3430-5. PubMed ID: 16380448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
